{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:29:45Z","timestamp":1791430185063,"version":"4.3.3"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Methadone was introduced in 2013 for the treatment of intractable cancer pain in Japan and is indicated for patients receiving opioid doses \u226760\u00a0mg\/day as an oral morphine equivalent. Low-dose (\u226610\u00a0mg\/day) add-on methadone to prior opioids has been reported from European countries to successfully relieve various types of intractable cancer pain; however, there are few reports of such use in Japan. The aim of this study was to analyze more than a hundred cases with low-dose add-on methadone to treat intractable pain in Japanese cancer patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>All cases in which 5 or 10\u00a0mg\/day of methadone was added to prior opioids by the Palliative Care Team or Division of Palliative Medicine in our hospital during the period between April 2016 and September 2023 were extracted and analyzed retrospectively on electrical medical charts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results and conclusions<\/jats:title>\n                  <jats:p>A total of 102 cases were extracted with a male-to-female ratio of\u00a060:42, and the age (mean\u00a0\u00b1\u00a0SD) was 62.8\u00a0\u00b1\u00a014.7\u00a0years old. Methadone was introduced in an inpatient setting to 86 patients. The major pathologies that caused intractable pain were spinal metastases in 48, pelvis or pelvic floor lesions in 29 and pleural and\/or chest wall lesions in 16. The most common mechanism of pain was the mixture of somatic and neuropathic components. The major opioids administered prior to methadone included tapentadol in 46 patients, hydromorphone in 36 and oxycodone in 19. The dose of the prior opioids [median, (interquartile range: IQR)] was 97, (62.8\u2013167.3) (range: 15\u20131313) mg\/day of oral morphine equivalent. Radiotherapy, chemotherapy and nerve blocks were performed as concomitant therapies in 48, 22 and 11 patients, respectively (with some overlap). The number of rescue doses [median (IQR)] was significantly decreased from three (two to five) on the day before methadone to one (zero to four) after seven days from methadone initiation. The side effects leading to discontinuation of methadone were drowsiness in three cases, nausea in three cases and dizziness in one case (with some overlap). Compared with complete switching from other opioids, low-dose add-on methadone can reduce the possibility of major dose discrepancies and can be quickly adjusted by combined opioid reduction\/increase. Low-dose add-on methadone can be an effective and safe method for intractable cancer pain.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyae156","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:27:54Z","timestamp":1730806074000},"page":"123-130","source":"Crossref","is-referenced-by-count":8,"title":["Low-dose add-on methadone for cancer pain management: a retrospective analysis of 102 Japanese patients"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8445-180X","authenticated-orcid":false,"given":"Tetsumi","family":"Sato","sequence":"first","affiliation":[{"name":"Shizuoka Cancer Center, Nagaizumi-cho, Shiuzoka Division of Palliative Medicine, ,","place":["Japan"]},{"name":"Shizuoka Cancer Center, Nagaizumi-cho, Shizuoka Palliative Care Team, ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Fukutomi","sequence":"additional","affiliation":[{"name":"Shizuoka Cancer Center, Nagaizumi-cho, Shiuzoka Division of Palliative Medicine, ,","place":["Japan"]},{"name":"Shizuoka Cancer Center, Nagaizumi-cho, Shizuoka Palliative Care Team, ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiichi","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Shizuoka Cancer Center, Nagaizumi-cho, Shiuzoka Division of Palliative Medicine, ,","place":["Japan"]},{"name":"Shizuoka Cancer Center, Nagaizumi-cho, Shizuoka Palliative Care Team, ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Shizuoka Cancer Center, Nagaizumi-cho, Shiuzoka Division of Palliative Medicine, ,","place":["Japan"]},{"name":"Shizuoka Cancer Center, Nagaizumi-cho, Shizuoka Palliative Care Team, ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Sato","sequence":"additional","affiliation":[{"name":"Shizuoka Cancer Center, Nagaizumi-cho, Shizuoka Palliative Care Team, ,","place":["Japan"]},{"name":"Shizuoka Cancer Center, Nagaizumi-cho Department of Pharmacy, ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Kamo","sequence":"additional","affiliation":[{"name":"Shizuoka Cancer Center, Nagaizumi-cho, Shizuoka Palliative Care Team, ,","place":["Japan"]},{"name":"Shizuoka Cancer Center, Nagaizumi-cho Department of Pharmacy, ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Shizuoka Cancer Center, Nagaizumi-cho, Shizuoka Palliative Care Team, ,","place":["Japan"]},{"name":"Shizuoka Cancer Center, Nagaizuim-cho Patient and Family Support Center, ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Hagiya","sequence":"additional","affiliation":[{"name":"Shizuoka Cancer Center, Nagaizumi-cho, Shizuoka Palliative Care Team, ,","place":["Japan"]},{"name":"Shizuoka Cancer Center, Nagaizuim-cho Patient and Family Support Center, ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rei","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Shonan University of Medical Sciences, Yokohama Faculty of Pharmaceutical Sciences, ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"2025020413014437000_ref1","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/j.jpainsymman.2021.09.011","article-title":"Pain prevalence during cancer treatment: a systematic review and meta-analysis","volume":"63","author":"Evenepoel","year":"2022","journal-title":"J Pain Symptom Manag"},{"key":"2025020413014437000_ref2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/NJH.0000000000000507","article-title":"Cancer pain and quality of life","volume":"21","author":"Rodriguez","year":"2019","journal-title":"J Hosp Palliat Nurs"},{"key":"2025020413014437000_ref3","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jpainsymman.2015.12.340","article-title":"Update on prevalence of pain in patients with cancer: systematic review and meta-analysis","volume":"51","author":"Beuken-van Everdingen","year":"2016","journal-title":"J Symptom Manage"},{"key":"2025020413014437000_ref4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012592.pub2","article-title":"Opioids for cancer pain \u2013 an overview of Cochrane reviews","volume":"7","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025020413014437000_ref5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/jpm.2011.0326","article-title":"Defining refractory pain in cancer for clinicians and researchers","volume":"15","author":"Currow","year":"2012","journal-title":"J Palliat Med"},{"key":"2025020413014437000_ref6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.12688\/f1000research.27809.1","article-title":"IMPORTANCE trial: a provisional study-design of a single-center, phase II, double-blinded, placebo-controlled, randomized, 4-week study to compare the efficacy and safety of intranasal esketamine in chronic opioid refractory pain","volume":"10","author":"Fernandes","year":"2021","journal-title":"F1000 Res"},{"key":"2025020413014437000_ref7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jpainsymman.2015.02.029","article-title":"Methods of rotation from another strong opioid to methadone for the management of cancer pain: a systematic review of the available evidence","volume":"50","author":"McLean","year":"2015","journal-title":"J Pain Symptom Manag"},{"key":"2025020413014437000_ref8","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0022-3565(25)10630-7","article-title":"Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception","volume":"274","author":"Codd","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"2025020413014437000_ref9","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0022-3565(24)38234-5","article-title":"D-methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia","volume":"289","author":"Davis","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"2025020413014437000_ref10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12904-022-01076-2","article-title":"Methadone switching for refractory cancer pain","volume":"21","author":"Ding","year":"2022","journal-title":"BMC Palliat Care"},{"key":"2025020413014437000_ref11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0304-3940(95)11364-3","article-title":"Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord","volume":"187","author":"Ebert","year":"1995","journal-title":"Neurosci Lett"},{"key":"2025020413014437000_ref12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/s1056-8719(00)00043-5","article-title":"Methadone: a review of its pharmacokinetic\/pharmacodynamic properties","volume":"42","author":"Garrido","year":"1999","journal-title":"J Pharmacol Toxicol Methods"},{"key":"2025020413014437000_ref13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3109\/15360288.2014.938883","article-title":"Therapeutic challenges in cancer pain management: a systematic review of methadone","volume":"28","author":"Good","year":"2014","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"2025020413014437000_ref14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/s0304-3940(97)13391-2","article-title":"The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord","volume":"223","author":"Gorman","year":"1997","journal-title":"Neurosci Lett"},{"key":"2025020413014437000_ref15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jpain.2020.04.004","article-title":"Methadone in pain management: a systemic review","volume":"22","author":"Hanna","year":"2021","journal-title":"J Pain"},{"key":"2025020413014437000_ref16","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s40263-020-00743-3","article-title":"Methadone for pain management: a pharmacological review","volume":"34","author":"Kreutzwiser","year":"2020","journal-title":"CNS Drugs"},{"key":"2025020413014437000_ref17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjspcare-2021-003220","article-title":"Methadone and neuropathic cancer pain subcomponents: a prospective cohort pilot study","volume":"13","author":"Fawoubo","year":"2023","journal-title":"BMJ Support Palliat Care"},{"key":"2025020413014437000_ref18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1155\/2003\/236718","article-title":"Methadone in the treatment of neuropathic pain","volume":"8","author":"Gagnon","year":"2003","journal-title":"Pain Res Manag"},{"key":"2025020413014437000_ref19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5055\/jom.2006.0040","article-title":"Methadone for cancer-related neuropathic pain: a review of the literature","volume":"5","author":"Mannino","year":"2006","journal-title":"J Opioid Manag"},{"key":"2025020413014437000_ref20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1191\/096813098673619329","article-title":"The use of methadone in cancer pain poorly responsive to other opioids","volume":"5","author":"Morley","year":"1998","journal-title":"Pain Rev"},{"key":"2025020413014437000_ref21","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.3390\/cancers14081992","article-title":"Treatment of neuropathic pain directly due to cancer: an update","volume":"14","author":"Shkodra","year":"2022","journal-title":"Cancer"},{"key":"2025020413014437000_ref22","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1089\/jpm.2015.0303","article-title":"A retrospective study on the effectiveness of switching to oral methadone for relieving severe cancer-related neuropathic pain and limiting adjuvant analgesic use in Japan","volume":"19","author":"Sugiyama","year":"2016","journal-title":"J Palliat Med"},{"key":"2025020413014437000_ref23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2023.1156618","article-title":"Management of pain in patients with bone metastases","volume":"13","author":"Jing","year":"2023","journal-title":"Front Oncol"},{"key":"2025020413014437000_ref24","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/00130404-200609000-00002","article-title":"Difficult pain syndromes: bone pain, visceral pain, and neuropathic pain","volume":"12","author":"Shaiova","year":"2006","journal-title":"Cancer J"},{"key":"2025020413014437000_ref25","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00520-020-05606-7","article-title":"The role of methadone in cancer-induced bone pain: a retrospective cohort study","volume":"29","author":"Sulistio","year":"2021","journal-title":"Support Care Cancer"},{"key":"2025020413014437000_ref26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00520-024-08706-w","article-title":"Methadone versus other opioids for refractory malignant bone pain: a pilot randomized controlled study","volume":"32","author":"Sulistio","year":"2024","journal-title":"Support Care Cancer"},{"key":"2025020413014437000_ref27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s005200000180","article-title":"Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration","volume":"9","author":"Davis","year":"2001","journal-title":"Support Care Cancer"},{"key":"2025020413014437000_ref28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0889-8588(02)00017-5","article-title":"The use of methadone for cancer pain","volume":"16","author":"Ripamonti","year":"2002","journal-title":"Hematol\/Oncol Clin"},{"key":"2025020413014437000_ref29","first-page":"577","article-title":"A systemic review of the cardiotoxicity of methadone","volume":"14","author":"Alinejad","year":"2015","journal-title":"EXCLI J"},{"key":"2025020413014437000_ref30","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1089\/jpm.2016.0411","article-title":"Methadone and corrected QT prolongation in pain and palliative care patients: a case-control study","volume":"20","author":"Juba","year":"2017","journal-title":"J Palliat Med"},{"key":"2025020413014437000_ref31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/1049909118811904","article-title":"Evaluation of QTc interval prolongation among patients with cancer using enteral methadone","volume":"36","author":"Lovell","year":"2019","journal-title":"Am J Hosp Palliat Care"},{"key":"2025020413014437000_ref32","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jpainsymman.2023.10.018","article-title":"Routine monitoring of QTc interval as a barrier for efficient use of methadone in palliative care","volume":"67","author":"Pawate","year":"2024","journal-title":"J Pain Symptom Manag"},{"key":"2025020413014437000_ref33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1089\/jpm.2009.0184","article-title":"The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study","volume":"13","author":"Reddy","year":"2010","journal-title":"J Palliat Med"},{"key":"2025020413014437000_ref34","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1016\/j.xphs.2018.08.025","article-title":"Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review","volume":"107","author":"Volpe","year":"2018","journal-title":"J Pharm Sci"},{"key":"2025020413014437000_ref35","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1089\/jpm.2016.0246","article-title":"Use of methadone as an adjuvant medication to low-dose opioids for neuropathic pain in the frail elderly: a case series","volume":"19","author":"Bach","year":"2016","journal-title":"J Palliat Med"},{"key":"2025020413014437000_ref36","doi-asserted-by":"publisher","DOI":"10.1089\/pmr.2020.0034","article-title":"Ultralow-dose adjunctive methadone with slow titration, considering long half-life, for outpatients with cancer-related pain","volume":"1","author":"Chary","year":"2020","journal-title":"Palliat Med Rep"},{"key":"2025020413014437000_ref37","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1089\/jpm.2016.0525","article-title":"Methadone as a coanalgesic for palliative care cancer patients","volume":"19","author":"Courtemanche","year":"2016","journal-title":"J Palliat Med"},{"key":"2025020413014437000_ref38","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3390\/life12050679","article-title":"The use of low-dose methadone as add-on to ongoing opioid treatment in palliative cancer care-an underrated treatment?","volume":"12","author":"F\u0171rst","year":"2022","journal-title":"Life"},{"key":"2025020413014437000_ref39","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/jpm.2017.0157","article-title":"Improved pain control in terminally ill cancer patients by introducing low-dose oral methadone in addition to ongoing opioid treatment","volume":"21","author":"F\u0171rst","year":"2018","journal-title":"J Palliat Med"},{"key":"2025020413014437000_ref40","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1089\/jpm.2019.0253","article-title":"The use of low-dose methadone as add-on to regular opioid therapy in cancer-related pain at end of life: a national Swedish survey in specialized palliative care","volume":"23","author":"F\u0171rst","year":"2020","journal-title":"J Palliat Med"},{"key":"2025020413014437000_ref41","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1191\/0269216303pm815oa","article-title":"Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial","volume":"17","author":"Morley","year":"2003","journal-title":"Palliat Med"},{"key":"2025020413014437000_ref42","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1089\/jpm.2012.0612","article-title":"The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia","volume":"16","author":"Salpeter","year":"2013","journal-title":"J Palliat Med"},{"key":"2025020413014437000_ref43","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/jpm.2012.0335","article-title":"Addition of methadone to another opioid in the management of moderate to severe cancer pain: a case series","volume":"16","author":"Wallace","year":"2013","journal-title":"J Palliat Med"},{"key":"2025020413014437000_ref44","doi-asserted-by":"publisher","first-page":"350","DOI":"10.55782\/ane-2021-34","article-title":"Synergistic analgesic effect of morphine and tramadol in non-sensitive and morphine-sensitive mice: an isobolographic study","volume":"81","author":"Khakpal","year":"2021","journal-title":"Acta Neurol Exp"},{"key":"2025020413014437000_ref45","first-page":"45","article-title":"The use of tramadol and morphine for pain relief after abdominal hysterectomy","volume":"32","author":"Kocabas","year":"2005","journal-title":"Clin Exp Obstet Gynecol"},{"key":"2025020413014437000_ref46","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40263-019-00660-0","article-title":"Opioid-induced tolerance and hyperalgesia","volume":"33","author":"Mercadante","year":"2019","journal-title":"CNS Drugs"},{"key":"2025020413014437000_ref47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyv108","article-title":"Methadone reverses analgesic tolerance induced by morphine pretreatment","volume":"19","author":"Posa","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"2025020413014437000_ref48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0885-3924(99)00121-9","article-title":"NMDA-receptor antagonists and opioid receptor interactions as related to analgesia and tolerance","volume":"19","author":"Price","year":"2020","journal-title":"J Pain Symptom Manag"},{"key":"2025020413014437000_ref49","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1089\/jpm.2006.9.488","article-title":"Rotating methadone to other opioids: a lesson in the mechanisms of opioid tolerance and opioid-induced pain","volume":"9","author":"Prommer","year":"2006","journal-title":"J Palliat Med"},{"key":"2025020413014437000_ref50","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/ejp.1196","article-title":"Comparative pharmacology and toxicology of tramadol and tapentadol","volume":"22","author":"Faria","year":"2018","journal-title":"Eur J Pain"},{"key":"2025020413014437000_ref51","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2165\/11589080-000000000-00000","article-title":"Tapentadol in pain management: a \u03bc-opioid receptor agonist and noradrenaline reuptake inhibitor","volume":"25","author":"Hartrick","year":"2011","journal-title":"CNS Drugs"},{"key":"2025020413014437000_ref52","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1517\/14656566.2012.696097","article-title":"Mechanistic and functional differentiation of tapentadol and tramadol","volume":"13","author":"Raffa","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"2025020413014437000_ref53","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40263-014-0151-9","article-title":"The mu-opioid receptor agonist\/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol","volume":"28","author":"Tzschentke","year":"2014","journal-title":"CNS Drugs"},{"key":"2025020413014437000_ref54","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00210-015-1167-5","article-title":"What is the main mechanism of tramadol?","volume":"388","author":"Minami","year":"2015","journal-title":"Naunyn Shmiedebergs Arch Pharmacol"},{"key":"2025020413014437000_ref55","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1001\/archinte.166.12.1280","article-title":"Drug-induced long QT syndrome in injection drug receiving methadone. High frequency in hospitalized patients and risk factors","volume":"166","author":"Ehret","year":"2006","journal-title":"Arch Intern Med"},{"key":"2025020413014437000_ref56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/oncolo\/oyae094","article-title":"Opioid metabolism and drug-drug interaction in cancer","volume":"XX","author":"Aapro","year":"2024","journal-title":"Oncologist"},{"key":"2025020413014437000_ref57","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41586-021-03769-9","article-title":"Structural basis of ketamine action on human NMDA receptors","volume":"596","author":"Zhang","year":"2021","journal-title":"Nature"},{"key":"2025020413014437000_ref58","doi-asserted-by":"publisher","first-page":"11158","DOI":"10.1523\/jneurosci.1547-16.2016","article-title":"Ketamine: NMDA receptors and beyond","volume":"36","author":"Zorumski","year":"2016","journal-title":"J Neurosci"},{"key":"2025020413014437000_ref59","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1089\/pmr.2023.0061","article-title":"Safety and efficacy of combined injection of pure-\u03bc-opioid agonist with tramadol as an opioid induction agent for opioid na\u00efve cancer patients","volume":"5","author":"Sato","year":"2024","journal-title":"Palliat Med Rep"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/2\/123\/60420326\/hyae156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/2\/123\/60420326\/hyae156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T13:02:03Z","timestamp":1738674123000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/2\/123\/7875931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,11,5]]},"published-print":{"date-parts":[[2025,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae156","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,11,5]]}}}